Immunologic Considerations in Heart Transplantation for Congenital Heart Disease

Beth D. Kaufman* and Robert E. Shaddy

From the Children’s Hospital of Philadelphia, and the University of Pennsylvania School of Medicine, Philadelphia, PA

Abstract: Children and adults with congenital heart disease (CHD) can require interventions that result in immunologic alterations that are different than those seen in patients with cardiomyopathies. Patients with CHD can be exposed to heart surgeries, blood products, valved and non-valved allograft tissue, and mechanical circulatory support, all of which can alter the immunologic status of these patients. This change in immunologic status is most commonly manifested as the development of anti-human leukocyte antigen (HLA) antibodies. This review will delineate a) the causes of anti-HLA antibody production (often referred to as allosensitization); b) preventive strategies for anti-HLA antibody production before transplantation; c) treatment strategies for those patients who develop anti-HLA antibodies before transplantation; d) consequences of HLA allosensitization after transplantation; and e) treatment of HLA allosensitization and antibody-mediated rejection after transplantation.

Keywords: Heart transplantation, allosensitization, rejection, pediatric, therapy, management.

CAUSES OF ANTI-HLA ANTIBODY PRODUCTION

Anti-HLA antibodies usually can be detected in the blood of individuals in response to an exposure to foreign antigens that stimulate their production. Various stimuli have been identified that result in the development of anti-HLA antibodies. These include pregnancy, transfusions of blood products, valved and non-valved allograft material (including whole organ transplant), and use of ventricular assist devices. Blood transfusions cause anti-HLA antibody production through exposure to antigenic stimuli such as white blood cells and/or platelets. Using filters and/or irradiation reduces the risk of HLA allosensitization, but does not appear to be entirely protective. Patients who undergo repair of CHD, especially if requiring cardiopulmonary bypass, usually are exposed to blood products either during or after surgery. Many patients with CHD, particularly those with complex CHD, often require multiple surgeries throughout their lifetimes, and therefore are exposed to multiple blood products and therefore multiple antigenic stimuli. Valved and non-valved allograft material is commonly used for the repair of CHD. Valved allograft material is used for repairs in the right and left ventricular outflow tracts, and much less commonly in the atroventricular valves. Non-valved allograft material is used primarily for aortic arch and pulmonary artery reconstruction, in addition to right and left ventricular outflow tracts. Regardless of its site of repair, allograft material used at the time of surgery provides a strong stimulus to the development of anti-HLA antibodies. This response occurs within weeks of implantation and can be detected as circulating very broad reactivity of anti-HLA antibodies for many years [1-5].

*Address correspondence to this author at the Division of Cardiology The Children’s Hospital of Philadelphia 34th St and Civic Center Blvd Philadelphia, PA 19104-4399; Tel: 267-426-2882; Fax: 215-590-1340; E-mails: kaufmanb@email.chop.edu; shaddyr@email.chop.edu

PREVENTIVE STRATEGIES FOR ANTI-HLA ANTIBODY PRODUCTION BEFORE TRANPLANTATION

Two basic strategies have been tried to prevent the development of anti-HLA antibodies in these situations: 1) the reduction and/or alteration of the antigenic stimulus, or 2) the alteration of the immune response of the individual to the antigenic stimulus. As stated above, using filters and/or irradiation for blood products may decrease the antigenic exposure to an individual, and the mechanism is thought to be primarily through the removal of allosensitizing white blood cells in blood products. Attempts to alter the antigenic load that is presented by allograft material has generally been directed toward removal of antigen-presenting cells on allograft material prior to implantation. These decellularized allografts have been shown to markedly reduce the degree of allosensitization seen after allograft implantation in both animals and in humans, but questions still remain as to the durability and safety of these altered allografts [6-9].

Methods to alter the immune system before or during allograft implantation has also met with some degree of success. In animal studies, drugs like cyclosporine and mycophenolic mofetil (MMF) have been successfully used to reduce the alloantibody response to allograft implantation [10, 11]. Peri-operative MMF (but not azathioepine) has also been shown to reduce the response to allograft implantation in children undergoing surgery for CHD [12-14]. Presumably, if patients with CHD were heavily immunosuppressed at the time of allograft implantation for repair of CHD (similar to heart transplantation), there would be significant reduction in the incidence and breadth of allosensitization. However, this level of immunosuppression carries with it significant risks including infectious and neoplastic complications, in addition to all of the drug-specific complications such as renal dysfunction, diabetes, etc. One of the factors limiting the application of all forms of immunosuppression after surgical
allograft implantation for CHD is the lack of convincing evidence that the anti-HLA antibody response to the allograft alters its function and/or longevity. Thus, it is difficult to justify routine immunosuppression in children with CHD who receive allograft material at the time of surgery.

The consequences of the development of anti-HLA antibodies in patients with CHD are a matter of debate [15]. Although one would theorize that the presence of donor-specific anti-HLA antibodies has potential for immune-mediated damage to the implanted allograft, it has never been conclusively proven that this is true. Some pathologic studies of explanted allografts in adults have failed to demonstrate evidence of immune-mediated damage (e.g., “rejection”) [16]. However, evidence of such immune injury in explanted allografts of children with CHD has been shown [17, 18]. There do not appear to be any other significant systemic adverse effects from these alloantibodies, unless these patients come to need heart or other solid organ transplantation. It has been well-recognized for many years that patients with circulating anti-HLA antibodies, especially those who have a subsequent incompatible HLA crossmatch because of these antibodies, are at increased risk for rejection and graft loss after transplantation for [19, 20]. Because of this, many centers continue to maintain a policy of requiring a prospective crossmatch (either actual crossmatch between donor and recipient, or virtual crossmatch based upon known HLA donor type and recipient anti-HLA antibodies. In these situations where a prospective crossmatch is required (either actual or virtual), wait times for organs are significantly increased due to the resultant reduction in potential donors, and therefore waitlist mortality is significantly increased. In pediatrics, wait times to transplant and mortality after listing have been shown to be double those who do not require a crossmatch [21]. Because of this, some centers have adopted a policy of not requiring a prospective crossmatch, and performing heart transplants with an incompatible HLA match. Using plasmapheresis, thymoglobulin, and increased immunosuppression, early results have been encouraging, and multicenter studies are underway [22-24].

**TREATMENT STRATEGIES FOR THOSE PATIENTS WHO DEVELOP ANTI-HLA ANTIBODIES BEFORE TRANSPLANTATION**

Many strategies have been tried to reduce this allosensitization before transplantation in order to optimize the opportunity for finding and transplanting an HLA-compatible organ. These strategies have included plasmapheresis, a procedure which involves extracorporeal removal and replacement of the entire plasma volume (containing antibodies as well as other proteins such as coagulation factors). Plasmapheresis requires placement of a large bore dual lumen catheter in a large central vein. This is often challenging in young children due to size of blood vessels, lack or minimal vascular access because of venous occlusions from previous catheters, and/or systemic venous anomalies. Exchange transfusions are often performed in children who are too small for vascular catheter placement and plasmapheresis. Additional strategies include immunosuppressant medications (such as cyclophosphamide), intravenous immune globulin (IVIG), rituximab, or some combination of these [25-27]. Most of these strategies have been able to demonstrate at least a modest, although transient, reduction in anti-HLA antibodies in some patients. Unfortunately, none of these strategies appear to result in a sustained reduction; furthermore, there is controversy as to whether this transient reduction in anti-HLA antibodies provides enough improvement in outcomes after transplantation to warrant the exposure to the medications, hospitalizations, and risks of these treatments.

**CONSEQUENCES OF HLA ALLOSENSITIZATION AFTER TRANSPLANTATION**

The presence of circulating anti-HLA antibodies before transplantation is associated with increased risk of rejection, graft vasculopathy, graft dysfunction, and death after transplantation [28-31]. Injury to the graft may be acute with hemodynamic dysfunction or more chronic manifesting as chronic rejection or graft vasculopathy. Donor specific anti-HLA antibodies (DSA) may be performed due to allosensitization prior to transplant, or develop de novo at any time following transplant. The de novo development of anti-HLA antibodies after heart transplantation correlates with decreased long term survival. Patients with de novo antibodies appearing more than one year following transplantation had the poorest survival; 47% at 15 years compared to 70-71% 15 year survival for those with none or only pre transplant anti-HLA antibodies [32].

Most investigations refer to results of generalized anti-HLA panel reactive antibody (PRA) assays rather than donor specific antibodies for determination of allosensitization status. Data from the United Network for Organ Sharing (UNOS) shows that elevated pretransplant PRA in adult heart transplant recipients is a strong predictor of rejection within 1 year after transplant and mortality [33]. The potential consequence of DSAs on transplant outcomes in children is less well established, and may not be the same as observed in adults due to putative age-related differences in the maturity of the immune system. The incidence of allosensitized pediatric heart transplant candidates appears to be increasing as our CHD population enjoys improved operative survival, only to eventually develop cardiac dysfunction following palliative repair. Coupled with a persistently limited pediatric donor supply, the impact of DSA on pediatric heart transplant outcomes is a current area of significant research efforts.

Data available for pediatric heart transplant recipients is generally limited by small sample sizes from single center reports with heterogeneous results due to variations in study design or antibody detection methods. There is a consensus that DSA can be detrimental to graft function, and associated with rejection, though findings related to impact of DSA on graft and patient survival is less uniform [21, 24, 34-36].

In a recent study from the UNOS registry, pediatric heart transplant recipients with PRA >10% had significantly worse graft and patient survival than those with none or PRA of 1%-10% [37]. Findings were independent of pretransplant status, year of transplantation, donor factors, crossmatch status, and rejection episodes in the first year after transplant. Fig. 1 [37].
There is increasing evidence that anti-HLA antibodies (elevated PRA) are involved in cardiac allograft injury, both acute and chronic, referred to as humoral or antibody-mediated rejection (AMR). Diagnostic criteria for AMR are controversial; however, they currently include clinical evidence of cardiac graft dysfunction, donor-specific anti-HLA antibodies in the serum, and pathologic findings on endomyocardial biopsy. These pathologic findings may include one or both of the following: histologic abnormalities (capillary injury with endothelial cell swelling, intravascular macrophage and/or neutrophil accumulation) as well as immunostaining abnormalities (immunofluorescent deposits of immunoglobulin and complement diffusely in the vasculature) [38, 39].

The most severe form of AMR is referred to as hyperacute rejection which occurs in the first hours after transplant, precipitated by the presence of pre-formed DSA in the circulation that activates the complement system resulting in severe lytic injury to the endothelium and the graft, resulting in severe dysfunction (similar mechanism as injury due to ABO incompatibility). Chronic complement activation with sublytic injuries may occur in transplant recipients with DSA and/or elevated PRA as an ongoing or intermittent process that results in AMR and graft dysfunction. Acute hemodynamic compromise with increased risk for death, and development of early transplant graft vasculopathy has been observed in both adults and children with AMR that occurs after the immediate postoperative period [31]. The development of AMR has a significant negative impact on 15 year graft survival, with only 16% survival in AMR(+) patients compared to 63% survival in those without AMR in one study [40]. Of the 23 patients with AMR in this study, 21 displayed cytotoxic DSA at the time of diagnosis. While the presence of DSA and elevated PRA have been associated with detrimental outcomes, the mechanism has not been directly studied in most clinical investigations. There is some debate as to the uniform ability of all anti-HLA antibodies to activate the complement system and cause graft injury. The potential for accommodation has also been considered.

**TREATMENT OF HLA ALLOSENSITIZATION AND ANTIBODY-MEDIATED REJECTION AFTER TRANSPLANTATION**

Treatment of antibody-mediated rejection following heart transplant is focused on elimination of circulating antibodies, inhibition of circulating antibodies, suppression of B cells, plasma cell depletion, and/or complement inhibition, in addition to support of graft function which is often impaired due to immune-mediated injury [41]. Attempts to remove antibody are most commonly performed with plasmapheresis. Sedation may be required for catheter placement, which has risks if the patient is experiencing hemodynamic compromise from AMR. Fluid shifts, calcium and other electrolyte flux, and systemic reactions to blood products used for plasma replacement, are other risks related to plasmapheresis and/or exchange transfusion. Immune apheresis (immunoadsorption) is an emerging modality to specifically remove circulating antibodies and immune complexes. Plasmapheresis is often accompanied by the use of high-dose IVIG for immunomodulation to block anti-HLA antibody activity and inhibit complement, as well as corticosteroids to further attenuate the negative effect of circulating antibodies. Therapies to specifically target B cells are often incorporated into treatment for AMR. Rituximab is a chimeric murine/human anti CD20 monoclonal antibody that is utilized to deplete B cells and interfere with antigen-presenting cell (APC) activity to attempt to reduce the risk of recurrent AMR. While most reports have shown utility in treating AMR, all are small case series with different response rates and treatment protocols, combining various doses of rituximab with IVIG, steroid and plasmapheresis. Serious infections are a notable side effect observed with rituximab therapy [42]. New therapies are constantly being sought since the current methods are not universally successful. Bortezomib is an example of a proteosome inhibitor that has anti plasma cell properties and therefore is a promising therapy for AMR. Effectiveness of bortezomib against AMR in kidney transplant recipients has been reported, as well as utility in reducing donor-
specific anti-human leukocyte antigen antibody [43]. This therapy remains in early stages of investigation.

Support of the patient with significant cardiac graft dysfunction due to AMR may require intravenous inotropes, (milrinone, dobutamine, dopamine) and even temporary mechanical circulatory support due to acute hemodynamic decompensation. Following an episode of AMR, a change and/or increase in doses of maintenance immunosuppression is often considered. This may entail replacement of cyclosporine with tacrolimus in patients receiving cyclosporine-based immunosuppression, change in antiproliferative agents from azathioprine to MMF, addition of rapamycin (mammalian target of rapamycin inhibitor), and/or corticosteroids.

Cardiac catheterization for assessment of hemodynamics and endomyocardial biopsies including immunohistochemistry examination should be considered within weeks after initiation of AMR therapy to help assess effectiveness of therapy. Graft dysfunction may be prolonged. Emergent listing for retransplantation can be considered if the above measures do not restore acceptable cardiac function. However, retransplantation in first 6 months following transplantation is not recommended by the International Society of Heart and Lung Transplantation (ISHLT) post transplant guidelines due to poor survival [44].

DISCLOSURES
None.

FINANCIAL SUPPORT
None.

REFERENCES
[1] Shaddy RE, Hunter DD, Osborn KA, et al. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. Circulation 1996; 94: 1063-7.
[2] Smith JD, Ogino H, Hunt D, Taylor RM, Rose ML, Yacoub MH. Humoral immune response to human aortic valve homografts. Ann Thorac Surg 1995; 60: S127-30.
[3] Hawkins JA, Breinholt JP, Lambert LM, et al. Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. J Thorac Cardiovasc Surg 2000; 119: 324-30.
[4] Breinholt JP, 3rd, Hawkins JA, Lambert LM, Fuller TC, Proffer T, Shaddy RE. A prospective analysis of the immunogenicity of cryopreserved nonvalved allografts used in pediatric heart surgery. Circulation 2000; 102: III179-82.
[5] Hooper DK, Hawkins JA, Fuller TC, Proffer T, Shaddy RE. Prospective follow-up of panel reactive antibodies in children 5-years following implantation of cryopreserved allografts. The Journal of Heart and Lung Transplantation 2004; 23: S168.
[6] Hawkins JA, Hillman ND, Lambert LM, et al. Immunogenicity of decellularized cryopreserved allografts in pediatric cardiac surgery: comparison with standard cryopreserved allografts. J Thorac Cardiovasc Surg 2003; 126: 247-52; discussion 52-3.
[7] Meyer SR, Campbell PM, Rutledge JM, et al. Use of an allograft patch in repair of hypoplastic left heart syndrome may complicate future transplantation. Eur J Cardiothorac Surg 2005; 27: 554-60.
[8] Tavakkol Z, Gelehrter S, Goldberg CS, Bove EL, Devaney EJ, Ohye RG. Superior durability of SynerGraft pulmonary allografts compared with standard cryopreserved allografts. Ann Thorac Surg 2005; 80: 1610-4.
[9] Hopkins RA, Jones AL, Wolfingarmer L, Moore MA, Bert AA, Lofland GK. Decellularization reduces calcification while improving both durability and 1-year functional results of pulmonary homograft valves in juvenile sheep. J Thorac Cardiovasc Surg 2009; 137: 907-13, 13e1-4.
[10] Schmitz-Rixen T, Megerman J, Colvin RB, Williams AM, Abbott WM. Immunosuppressive treatment of aortic allografts. J Vasc Surg 1988; 7: 92.
[11] Wagner E, Roy R, Marois Y, Douville Y, Guidoin R. Fresh venous allografts in peripheral arterial reconstruction in dogs. Effects of histocompatibility and of short-term immunosuppression with cyclosporine A and mycophenolate mofetil. J Thorac Cardiovasc Surg 1995; 110: 1732-44.
[12] Shaddy RE, Lambert LM, Fuller TC, et al. Prospective randomized trial of azathioprine in cryopreserved valved allografts in children. Ann Thorac Surg 2001; 71: 43-7; discussion 7-8.
[13] Shaddy RE, Fuller TC, Anderson JB, et al. Mycophenolic acid reduces the HLA antibody response of children to valved allograft implantation. Ann Thorac Surg 2004; 77: 1734-9; discussion 9.
[14] Anderson JB, Fuller TC, Hawkins JA, Brinkman MK, Proffer T, Shaddy RE. Two-year reduction of panel reactive human leukocyte antigen antibodies in children receiving mycophenolate mofetil after valved allograft placement. Transplantation 2005; 80: 414-18.
[15] Shaddy RE, Fuller TC. The sensitized pediatric heart transplant candidate: causes, consequences, and treatment options. Pediatr Transplant 2005; 9: 208-14.
[16] Mitchell RN, Jonas RA, Schoen FI. Pathology of explanted cryopreserved allograft heart valves: comparison with aortic valves from orthotopic heart transplants. J Thorac Cardiovasc Surg 1998; 115: 118-27.
[17] Rajani B, Mee RB, Ratliff NB. Evidence for rejection of homograft cardiac valves in infants. J Thorac Cardiovasc Surg 1998; 115: 111-7.
[18] Vogt PR, Stammach T, Niederhauser U, et al. Explanted cryopreserved allografts: a morphological and immunohistochemical comparison between arterial allografts and allograft heart valves from infants and adults. Eur J Cardiothorac Surg 1999; 15: 639-44; discussion 44-5.
[19] Lavee J, Kormos RL, Duquesnoy RJ, et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant 1991; 10: 921-9; discussion 9-30.
[20] Kobashigawa JA, Sabad A, Drinkwater D, et al. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation 1996; 94: II294-7.
[21] Feingold B, Bowman P, Zeevi A, et al. Survival in allosensitized children after listing for cardiac transplantation. J Heart Lung Transplant 2007; 26: 565-71.
[22] Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999; 18: 701-6.
[23] Pollock-Babiz SM, den Hollander N, Ngan BY, et al. Pediatric heart transplantation in human leukocyte antigen sensitized patients: evolving management and assessment of intermediate-term outcomes in a high-risk population. Circulation 2007; 116: 1172-8.
[24] Holt DB, Lubin DM, Phelan DL, et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. J Heart Lung Transplant 2007; 26: 876-82.
[25] Itescu S, Burke E, Lietz K, et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 2002; 105: 1214-9.
[26] Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immunoglobulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-51.
[27] John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999; 100: II29-35.
[28] Hammond EH, Ensley RD, Yowell RL, et al. Vascular rejection of human cardiac allografts and the role of humoral immunity in chronic allograft rejection. Transplant Proc 1991; 23: 26-30.
Immunologic Considerations in Heart Transplantation for Congenital Heart Disease

[29] Rose EA, Pepino P, Barr ML, et al. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant 1992; 11: S120-3.

[30] Itescu S, Tung TC, Burke EM, et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 1998; 98: 786-93.

[31] Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 58-69.

[32] Ho EK, Vlad G, Vasilescu ER, et al. Pre- and posttransplantation allostimulation in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival. Hum Immunol 2010.

[33] Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA, Conte JV. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg 2007; 84: 1556-62; discussion 62-3.

[34] Jacobs JP, Quintessenza JA, Boucek RJ, et al. Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thorac Surg 2004; 78: 1703-9.

[35] Di Filippo S, Girnita A, Webber SA, et al. Impact of ELISA-detected anti-HLA antibodies on pediatric cardiac allograft outcome. Hum Immunol 2005; 66: 513-8.

[36] Xydas S, Yang JK, Burke EM, et al. Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 1289-96.

[37] Rossano JW, Morales DL, Zafar F, et al. Impact of antibodies against human leukocyte antigens on long-term outcome in pediatric heart transplant patients: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg 2010; 140: 694-9, e1-2.

[38] Berry GI, Angelini A, Burke MM, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: Evolution and current status (2005-2011). J Heart Lung Transplant 2011; 30: 601-11.

[39] Kfoury AG, Hammond ME. Controversies in defining cardiac antibody-mediated rejection: need for updated criteria. J Heart Lung Transplant 2010; 29: 389-94.

[40] Ho EK, Chan FL, Leong JC. Postsurgical recurrent stress fracture in the spine affected by ankylosing spondylitis. Clin Orthop Relat Res 1989; 87-9.

[41] Nair N, Ball T, Uber PA, Mehra MR. Current and future challenges in therapy for antibody-mediated rejection. J Heart Lung Transplant 2011; 30: 612-7.

[42] Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando) 2009; 23: 34-46.

[43] Flechner SM, Fatica R, Askar M, et al. The Role of Proteasome Inhibition With Bortezomib in the Treatment of Antibody-Mediated Rejection After Kidney-Only or Kidney-Combined Organ Transplantation. Transplantation. Transplantation 2010.

[44] Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29: 914-56.